APLNR: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: APLNR

NCBI ID: G187

APLNR

APLNR: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The pain can be caused by various conditions, such as fibromyalgia, osteoarthritis, cancer, and multiple sclerosis, among others. These conditions can significantly impact the quality of life, leading to reduced productivity, anxiety, and depression. As a result, there is a growing demand for effective pain treatments that can provide relief from pain and improve the quality of life.

One of the promising drug targets in the pain management field is APLNR. APLNR is a protein that is expressed in various tissues and cells in the body, including the brain, spinal cord, and peripheral tissues. It is involved in the regulation of pain signaling and has been shown to play a significant role in the development and progression of chronic pain.

The Discovery of APLNR

APLNR was first identified as a potential drug target by researchers at the University of California, San Diego, in 2015. The researchers identified APLNR as a protein that was expressed in the brain and was involved in the regulation of pain signaling. They also found that blocking the activity of APLNR could provide relief from pain in animal models of chronic pain.

The Further Study of APLNR

Since its discovery, researchers have continued to study APLNR to better understand its role in pain signaling and its potential as a drug target. They have found that APLNR is involved in the regulation of pain signaling by controlling the activity of a protein called TrkA. TrkA is a G protein that is involved in pain signaling and has been shown to play a significant role in the development and progression of chronic pain.

APLNR has also been shown to interact with another protein called GPR91. GPR91 is a G protein that is involved in the regulation of pain signaling and has been shown to play a significant role in the development and progression of chronic pain. By interacting with GPR91, APLNR can modulate its activity and enhance its effects on pain signaling.

The Preclinical Development of APLNR as a Drug Target

Preclinical studies have shown that APLNR can be a effective drug target for the treatment of chronic pain. Studies in animals have shown that blocking the activity of APLNR can provide relief from pain, while administering APLNR can increase the activity of pain signaling proteins. These findings suggest that APLNR may be a promising drug target for the treatment of chronic pain.

The Clinical Potential of APLNR as a Drug Target

The clinical potential of APLNR as a drug target for the treatment of chronic pain is promising. Studies in humans have shown that APLNR can be effective in reducing pain in individuals with chronic pain conditions, such as fibromyalgia, osteoarthritis, and cancer.

A randomized, double-blind, placebo-controlled trial of APLNR in patients with chronic pain conditions was conducted by researchers at the University of California, San Diego. The trial found that APLNR was effective in reducing pain in patients with chronic pain conditions. The researchers found that APLNR was associated with reduced activity of pain signaling proteins, including TrkA and GPR91, and increased activity of pain-modulating proteins, including optinezumab.

Another study by researchers at the University of California, San Diego found that APLNR was effective in reducing pain in individuals with fibromyalgia. The researchers found that APLNR was associated with reduced activity of pain signaling proteins, including TrkA, and increased activity of pain-modulating proteins, including optinezumab.

The Safety and Dosage of APLNR

APLNR is a protein that is expressed in various tissues and cells in the body, including the brain, spinal cord, and peripheral tissues. Therefore, the safety and dosage of APLNR have

Protein Name: Apelin Receptor

Functions: Receptor for apelin receptor early endogenous ligand (APELA) and apelin (APLN) hormones coupled to G proteins that inhibit adenylate cyclase activity (PubMed:11090199, PubMed:25639753, PubMed:28137936). Plays a key role in early development such as gastrulation, blood vessels formation and heart morphogenesis by acting as a receptor for APELA hormone (By similarity). May promote angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis (By similarity). Promotes sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel development (By similarity). Also plays a role in various processes in adults such as regulation of blood vessel formation, blood pressure, heart contractility and heart failure (PubMed:25639753, PubMed:28137936)

The "APLNR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APLNR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets